

## 2.7.6 Synopses of Individual Studies

### 2.7.6.1 Produktieve hoest: tijd of broomhexine? Een dubbelblind gerandomiseerd onderzoek [Productive cough: Thyme or bromhexine? A double-blind randomised investigation] Knols et al 1994.

Name of Sponsor/Company: -	Individual Study Table	<i>(For National Authority Use only)</i>
Name of Finished Product: -	Referring to Part of the Dossier <b>module 5</b>	
Name of active substance: <b>Thyme syrup</b>	Volume: Page:	
Title of Study:	<b>Produktieve hoest: tijd of broomhexine? Een dubbelblind gerandomiseerd onderzoek</b>	
Investigators:	<b>Knols G, Stal PC, Van Ree JW</b>	
Study centre (s):	<b>5 medicinal practices</b>	
Publication (reference)	<b>(8)</b>	
Studied period (years):	<b>Between December 1992 and March 1993</b>	Phase of development:
Objectives:	<b>Effect of treatment on symptoms of productive cough</b>	
Methodology:	<b>Randomised, double-blind, comparative study</b>	
Number of patients (planned and analyzed):	<b>60</b>	
Diagnosis and main criteria for inclusion:	<b>Complaints associated with productive cough</b>	
Test product, dose and mode of administration, batch number:	<b>Thyme syrup syrup (no details regarding DER, extraction solvent and amount of herbal preparation in the syrup). Oral administration, 3 x 10 ml daily.</b>	
Duration of treatment:	<b>5 days</b>	
Reference therapy, dose and mode of administration, batch number	<b>Bromhexine forte No further information on dose and mode of administration</b>	
Criteria for evaluation:	Efficacy: <b>Subjective evaluation of symptoms associated with productive cough</b>  Safety: <b>Not mentioned</b>	
Statistical methods:	<b>Not available</b>	
Results	Efficacy: <b>In both groups similar improvements. Improvement in smoking subjects seem to be delayed.</b>  Safety: <b>Not mentioned</b>	

## 2.7.6.2 Company report cited in an ESCOP monograph

Name of Sponsor/Company: <b>Dentinox Gesellschaft KG, Berlin</b>	Individual Study Table	<i>(For National Authority Use only)</i>
Name of Finished Product: <b>Hustagil® Thymian Hustensaft</b>	Referring to Part of the Dossier <b>module 5</b>	
Name of active substance: <b>Thyme syrup</b>	Volume: Page:	
Title of Study:	<b>Integrierter Abschlussbericht vom 04.12.1997 für Dentinox Gesellschaft KG, Berlin. Anwendung von Hustagil® Thymian Hustensaft bei Kindern mit Erkältungskrankheiten der oberen Luftwege oder mit Beschwerden der Bronchitis.</b>	
Investigators:	<b>Not mentioned</b>	
Study centre (s):	<b>Not specified</b>	
Publication (reference)	<b>Report is cited in (2)</b>	
Studied period (years):	<b>Not specified</b>	Phase of development:
Objectives:	<b>Effect of treatment on intensity of cough</b>	
Methodology:	<b>Randomised, double-blind, multicenter study</b>	
Number of patients (planned and analyzed):	<b>154</b>	
Diagnosis and main criteria for inclusion:	<b>Children with bronchial catarrh or bronchitis</b>	
Test product, dose and mode of administration, batch number:	<b>Thyme syrup syrup (containing 97.6 mg of thyme fluid extract (2-2.5:1) per ml). Oral administration, 15-30 ml daily.</b>	
Duration of treatment:	<b>7-14 days (mean 7.9 days)</b>	
Reference therapy, dose and mode of administration, batch number	-	
Criteria for evaluation:	<p>Efficacy: <b>Assessment of cough intensity (criteria for evaluation not mentioned).</b></p> <p>Safety: <b>Not mentioned</b></p>	
Statistical methods:	<b>Not available</b>	
Results	<p>Efficacy: <b>Compared to the start of the treatment an improvement in the intensity of coughing was reported in 93.5% of patients.</b></p> <p>Safety: <b>Not mentioned</b></p>	